|
|
 |
 | Medical News Releases > Faculty Experts at Washington University in St. Louis >
director of the pharmacology core at the Siteman Cancer Center
Expertise: pharmacogenetics, pharmacology, translational research, tumor markers, chemotherapy
Bio: There is a high degree of variation in patient response to medicines. The McLeod laboratory uses genetic tools to perform in vitro, ex vivo, and clinical evaluations to discover, validate, and apply molecular predictors of therapeutic outcome. This includes candidate gene and genome-wide human association studies, computational and functional characterization of newly discovered genetic variants, and the use of multiple strains of inbred mice to provide a broadbased approach to understand inherited sources of variability in drug effect.
Education:
-
Doctoral Degree in Pharmacology at Philadelphia College of Pharmacy and Science
| News Stories & Tip Sheets: |
Showing Stories 1 through 5 of 7.
- Show More |
|
Choosing tumor treatment
Cancer therapy based on anatomical location may soon be obsolete
April 18,
2006 -- The results of a new study at the School of Medicine could eventually have oncologists removing their specialties from their shingles by making therapy based on a tumor's anatomical location obsolete. When the researchers compared eight different kinds of cancerous tumors, they saw that whether the tumor was, for instance, a breast tumor, lung tumor or colon tumor didn't correlate to how the cancers interacted with a standard anticancer drug.
|
Genetic side effects
Genes' influence on common drugs may affect health-care quality, cost
Jan. 4,
2006 -- Chances are good that a medication you take is one of several drugs that can be affected by genetic factors, according to researchers at the School of Medicine and the St. Louis College of Pharmacy. They found that 29 percent of patients seen at local primary-care offices had taken at least one of 16 drugs that can cause adverse reactions in genetically susceptible people.
|
Gene specific
Survival of heart patients on beta-blockers varies greatly with genetic variation
Sept. 27,
2005 -- Survival of heart attack and unstable angina patients placed on beta-blocker therapy corresponds to specific variations in their genes, according to a study by researchers at the School of Medicine and the Mid America Heart Institute in Kansas City.
|
Designer treatment
$10 million grant enables research on gene-guided chemotherapy
Aug. 29,
2005 -- Taking into account that each of us has unique physical characteristics partly determined by variations in our genes, pharmacogenetics researchers at the School of Medicine are finding ways to personalize cancer treatments.
|
Tailoring treatment
Profile of tumor genes shows need for individualized chemotherapy
May 10,
2005 --
 |
| A look at the activity of 24 genes in 52 patients as those genes respond to the chemotherapy drug 5-fluorourancil |
Oncologists aren't sure exactly why patients with the same cancer often respond very differently to the same treatment, but a growing body of evidence suggests the answer lies somewhere in the genes. Now researchers at Washington University School of Medicine in St. Louis have become the first to profile the activity of whole sets of genes involved in processing chemotherapeutic drugs.
|
Showing Stories 1 through 5 of 7.
- Show More |
|
| Clips: |
Showing 2 Clips.
|
|
Cancer's location may not guide treatment
Forbes.com
and 2 others
May 12,
2006 -- Cancer drug therapy based on a tumor's location in the body may eventually become obsolete, a new study suggests.
WUSTL specialist Howard McLeod, director of the pharmacology core at the Siteman Cancer Center, says that drug effect is independent of where the tumor came from in the body.
|
Beta-Blocker Drugs May Pose Dangers for Some
Forbes.com
and 10 others
Sept. 28,
2005 -- Widely used beta-blocker blood pressure medications can raise the risk of death in patients with specific genes who receive the drugs after a heart attack or unstable angina, according to a study led by WUSTL researchers David Lanfear and Howard McLeod. Another study scheduled to begin at WUSTL will look for the appropriate treatments for patients whose genetic makeup might make beta-blocker use hazardous.
|
Affiliated with Barnes-Jewish Hospital and St. Louis Children's Hospital, members of BJC HealthCare.
Please contact us and let us know how we can assist you.
Technical problems with this Web site? Email questions or comments.
Please review the WUSTL News & Information copyright/privacy policy.
| |
|
| | |
|
Print ready page